Amicus Therapeutics grew revenue 33% last year, according to 2024 financial results released Wednesday.

The Princeton biotechnology company, which has its gene therapy research operations in Philadelphia, reported total revenue of $528.3 million, up from $399.4 million the previous year.

The 23-year-old company, which went public in 2007 and has grown to more than 500 employees, said it is on track to surpass $1 billion in total sales in 2028.

“We have a clear path to deliver continued revenue growth and accelerating profitability in 2025 and the years ahead,” said Bradley Campbell, the company’s CEO, in an investor call Wednesday morning. “We have firmly established Amicus as a unique biotechnology company.”

Amicus, which focuses on rare diseases, has two medicines in the market: Galafold, a treatment for Fabry disease, and Pombiliti+Opfolda, a combination therapy for Pompe disease.

Read More